Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts
Retrieved on:
木曜日, 10月 22, 2020
Other Consumer, Infectious diseases, Clinical trials, Philanthropy, Biotechnology, Pharmaceutical, Consumer, Health, Foundation, Other Philanthropy, Infectious diseases, Medical specialties, Medicine, RTT, Neglected tropical diseases, Tropical diseases, Helminthiases, Spirurida, Onchocerciasis, Lymphatic filariasis, Ivermectin, Filariasis, Merck, the MECTIZAN® Donation Program
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).
Key Points:
- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).
- The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases.
- After months of careful assessment, in July, WHO released a decision-making framework for resuming MDA during the ongoing pandemic.
- The SARS-CoV-2 pandemic is especially challenging for communities that continue to be threatened by river blindness and lymphatic filariasis.